We found that BLCA patients categorized into UCHL5 high-expression group showed significantly higher enrichment scores for the AKT/mTOR pathway (Figure 4E, p < 0.05) compared with BLCA patients in the UCHL5 low-expression group. The gene discussed is MTOR; the disease is bladder transitional cell carcinoma.